169 related articles for article (PubMed ID: 37761830)
1. Whole-Exome Sequencing Reveals High Mutational Concordance between Primary and Matched Recurrent Triple-Negative Breast Cancers.
Kaur J; Chandrashekar DS; Varga Z; Sobottka B; Janssen E; Gandhi K; Kowalski J; Kiraz U; Varambally S; Aneja R
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761830
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419.
Routh ED; Van Swearingen AED; Sambade MJ; Vensko S; McClure MB; Woodcock MG; Chai S; Cuaboy LA; Wheless A; Garrett A; Carey LA; Hoyle AP; Parker JS; Vincent BG; Anders CK
Front Oncol; 2022; 12():818693. PubMed ID: 35992833
[TBL] [Abstract][Full Text] [Related]
3. Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene.
Niyomnaitham S; Parinyanitikul N; Roothumnong E; Jinda W; Samarnthai N; Atikankul T; Suktitipat B; Thongnoppakhun W; Limwongse C; Pithukpakorn M
PeerJ; 2019; 7():e6501. PubMed ID: 30828495
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer.
Hercules SM; Liu X; Bassey-Archibong BBI; Skeete DHA; Smith Connell S; Daramola A; Banjo AA; Ebughe G; Agan T; Ekanem IO; Udosen J; Obiorah C; Ojule AC; Misauno MA; Dauda AM; Egbujo EC; Hercules JC; Ansari A; Brain I; MacColl C; Xu Y; Jin Y; Chang S; Carpten JD; Bédard A; Pond GR; Blenman KRM; Manojlovic Z; Daniel JM
Cancer Causes Control; 2022 Jun; 33(6):831-841. PubMed ID: 35384527
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts.
Hutchinson KE; Yost SE; Chang CW; Johnson RM; Carr AR; McAdam PR; Halligan DL; Chang CC; Schmolze D; Liang J; Yuan Y
Clin Cancer Res; 2020 Feb; 26(3):657-668. PubMed ID: 31611282
[TBL] [Abstract][Full Text] [Related]
6. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.
Jovanović B; Sheng Q; Seitz RS; Lawrence KD; Morris SW; Thomas LR; Hout DR; Schweitzer BL; Guo Y; Pietenpol JA; Lehmann BD
BMC Cancer; 2017 Apr; 17(1):241. PubMed ID: 28376728
[TBL] [Abstract][Full Text] [Related]
7. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST).
Astolfi A; Urbini M; Indio V; Nannini M; Genovese CG; Santini D; Saponara M; Mandrioli A; Ercolani G; Brandi G; Biasco G; Pantaleo MA
BMC Genomics; 2015 Nov; 16():892. PubMed ID: 26531060
[TBL] [Abstract][Full Text] [Related]
8. Distinct Gene Expression Profiles of Matched Primary and Metastatic Triple-Negative Breast Cancers.
Kaur J; Chandrashekar DS; Varga Z; Sobottka B; Janssen E; Kowalski J; Kiraz U; Varambally S; Aneja R
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626050
[TBL] [Abstract][Full Text] [Related]
9. Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.
Kriegsmann M; Endris V; Wolf T; Pfarr N; Stenzinger A; Loibl S; Denkert C; Schneeweiss A; Budczies J; Sinn P; Weichert W
Oncotarget; 2014 Oct; 5(20):9952-65. PubMed ID: 25296970
[TBL] [Abstract][Full Text] [Related]
10. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
Wang L; Zhai Q; Lu Q; Lee K; Zheng Q; Hong R; Wang S
Ann Med; 2021 Dec; 53(1):1358-1369. PubMed ID: 34396843
[TBL] [Abstract][Full Text] [Related]
11. Mutational Analysis of Triple-Negative Breast Cancer Using Targeted Kinome Sequencing.
Yoo TK; Lee WS; Kim J; Kim MK; Park IA; Kim JH; Han W
J Breast Cancer; 2022 Jun; 25(3):164-177. PubMed ID: 35657000
[TBL] [Abstract][Full Text] [Related]
12. Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing.
Heydt C; Rehker J; Pappesch R; Buhl T; Ball M; Siebolts U; Haak A; Lohneis P; Büttner R; Hillmer AM; Merkelbach-Bruse S
Sci Rep; 2020 Jul; 10(1):11387. PubMed ID: 32647293
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
14. An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing.
Malhotra R; Javle V; Tanwar N; Gowda P; Varghese L; K A; Madhusudhan N; Jaiswal N; K S B; Chatterjee M; Prabhash K; Sreekanthreddy P; Rishi KD; Goswami HM; Veldore VH
Front Oncol; 2023; 13():1002792. PubMed ID: 36994199
[TBL] [Abstract][Full Text] [Related]
15. A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay.
Chaudhary R; Quagliata L; Martin JP; Alborelli I; Cyanam D; Mittal V; Tom W; Au-Young J; Sadis S; Hyland F
Transl Lung Cancer Res; 2018 Dec; 7(6):616-630. PubMed ID: 30505706
[TBL] [Abstract][Full Text] [Related]
16. Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases.
Schrijver WAME; Selenica P; Lee JY; Ng CKY; Burke KA; Piscuoglio S; Berman SH; Reis-Filho JS; Weigelt B; van Diest PJ; Moelans CB
Cancer Res; 2018 Jun; 78(12):3112-3121. PubMed ID: 29615433
[TBL] [Abstract][Full Text] [Related]
17. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
[TBL] [Abstract][Full Text] [Related]
18. Whole exome sequencing reveals the genetic heterogeneity and evolutionary history of primary gliomas and matched recurrences.
Xu PF; Li C; Xi SY; Chen FR; Wang J; Zhang ZQ; Liu Y; Li X; Chen ZP
Comput Struct Biotechnol J; 2022; 20():2235-2246. PubMed ID: 35615029
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Munzone E; Gray KP; Fumagalli C; Guerini-Rocco E; Láng I; Ruhstaller T; Gianni L; Kammler R; Viale G; Di Leo A; Coates AS; Gelber RD; Regan MM; Goldhirsch A; Barberis M; Colleoni M
Breast Cancer Res Treat; 2018 Jul; 170(2):351-360. PubMed ID: 29589138
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors.
Pedersen MH; Hood BL; Beck HC; Conrads TP; Ditzel HJ; Leth-Larsen R
Oncoimmunology; 2017; 6(5):e1305531. PubMed ID: 28638726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
